Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Almost two-thirds of the adult American population is overweight. Obesity is associated with a higher incidence of hypertension, dyslipidemia, diabetes mellitus and coronary artery disease. Orlistat, a gastrointestinal lipase inhibitor, provides an option for weight loss management in addition to diet and exercise. This study assessed the metabolic response of patients with type 2 diabetes mellitus to orlistat. Forty-one patients with type 2 diabetes who received orlistat in a private endocrinology practice were identified by a computer-assisted retrospective chart review. Orlistat's effects on weight, blood pressure, lipid parameters, hemoglobin A1C (HbA1C), and concurrent medication use were identified. Analysis of the 23 patients who remained on the drug for a minimum of 3 months revealed statistically significant reductions in patient weight, body mass index (BMI), total cholesterol, HDL cholesterol, and LDL cholesterol levels. For patients with type 2 diabetes who were able to tolerate the drug, orlistat was associated with improvement in several cardiovascular risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“who are overweight with IGT), changes in lifestyle, including weight loss, decreased the incidence of diabetes by 58%.(46) Weight loss is associated with a decrease in insulin resistance, which is an important mechanism in the pathogenesis of type 2 diabetes.”
BackgroundPrevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
The Disease Burden Associated With Overweight and Obesity
Must, A. (1999) · JAMA · doi:10.1001/jama.282.16.1523 · Cited by 4,780
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Research works printed but not linked: 8
- 10.1001/archinte.1994.00420190068008 · doi:10.1001/archinte.1994.00420190068008 · Paper page
- 2000, Xenical [package insert].
- Busch R.S., 1998, Obesity Res., 5, 4S
- Chan J.C.N., 2001, Diabetes., 50, A108
- Bray G.A., 2001, Diabetes., 50, A107
- Deerochanawong C., 2001, Diabetes., 50, A433
- Shi Y.F., 2001, Diabetes., 50, A101
- National Heart, Lung, and Blood Institute., 2001, Third Report of the National Cholesterol Education Program Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Cited by
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004096.pub2 · Cited by 113
Ahmad, N. N., Robinson, S., Kennedy‐Martin, T., Poon, J. L., & Kan, H. (2021) · Obesity Reviews · doi:10.1111/obr.13326 · Cited by 69
“failed to demonstrate any significant changes.(24) Resolution of baseline prediabetes occurred in fewer orlistat-treated patients with obesity compared with liraglutide-treated patients in a Spanish observational study and more patients progressed to T2DM (6.”
BackgroundResultInfluentialEffectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Metadata
- Authors
- Allie, E. C., Kane, M. P., Busch, R. S., Bakst, G., & Hamilton, R. A.
- Affiliations
- Albany College of Pharmacy and Health Sciences (US)
- Endocrine Group, LLP, Albany, NY
- Corresponding author
- Allie, Edward C.
- Venue
- Hospital Pharmacy
- Publisher
- SAGE Publications
- Published
- 2004-01
- Volume
- 39
- Issue
- 1
- Pages
- 37-42
- ISSN
- 0018-5787 (ISSN-L)
- 1945-1253
- OpenAlex
- W2509590045
- Cited by
- 3
- References
- 39
- Citations by year
- 2024: 1 · 2021: 1
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Hospital Pharmacy (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- orlistat, type 2 diabetes, obesity, weight loss, lipase inhibitors, glycemic control, HbA1c, lipid profile, blood pressure, cardiovascular risk factors, body mass index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects. https://app.cochat.ai/papers/10.1177/001857870403900114
- The paper
- Allie, E. C., Kane, M. P., Busch, R. S., Bakst, G., & Hamilton, R. A. (2004). Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects. Hospital Pharmacy. https://doi.org/10.1177/001857870403900114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.